Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Merck
Mallinckrodt
Baxter
Boehringer Ingelheim

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AURANOFIN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Auranofin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00246064 The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol Completed Centocor Ortho Biotech Services, L.L.C. Phase 4 2001-12-01 The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid Arthritis (RA) during methotrexate tapering.
NCT01419691 Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed Kansas Bioscience Authority Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01419691 Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed The Leukemia and Lymphoma Society Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01419691 Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed Therapeutics for Rare and Neglected Diseases (TRND) Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01419691 Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed University of Kansas Medical Center Phase 2 2011-09-01 The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
NCT01737502 Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2012-11-01 This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer.
NCT01737502 Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting Mayo Clinic Phase 1/Phase 2 2012-11-01 This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Auranofin

Condition Name

Condition Name for Auranofin
Intervention Trials
HIV 2
Ovarian Serous Tumor 1
Recurrent Ovarian Epithelial Cancer 1
Chronic Lymphocytic Leukemia (CLL) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Auranofin
Intervention Trials
Lung Neoplasms 2
Dysentery, Amebic 2
Carcinoma, Non-Small-Cell Lung 2
Amebiasis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Auranofin

Trials by Country

Trials by Country for Auranofin
Location Trials
United States 8
Germany 1
Bangladesh 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Auranofin
Location Trials
Minnesota 3
Florida 2
Kansas 2
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Auranofin

Clinical Trial Phase

Clinical Trial Phase for Auranofin
Clinical Trial Phase Trials
Phase 4 1
Phase 2 4
Phase 1/Phase 2 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Auranofin
Clinical Trial Phase Trials
Recruiting 5
Completed 2
Withdrawn 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Auranofin

Sponsor Name

Sponsor Name for Auranofin
Sponsor Trials
Mayo Clinic 5
National Cancer Institute (NCI) 4
National Institute of Allergy and Infectious Diseases (NIAID) 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Auranofin
Sponsor Trials
Other 16
NIH 7
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Harvard Business School
Moodys
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.